Oxford Nanopore Technologies today announced an expanded partnership with UPS Healthcare to accelerate the delivery of Oxford Nanopore DNA/RNA sequencing products and supplies in the Asia Pacific region.This partnership will strengthen Oxford Nanopore’s real-time mobile DNA sequencing equipment supply chain in key Asian markets. By leveraging UPS specialized healthcare logistics solutions, Oxford Nanopore customers will benefit from faster deliveries with less complexity, eliminating many customer pain points and allowing more time for further research as well as high-impact and time-sensitive genomic exploration in areas such as human disease, cancer, and agriculture.The Oxford Nanopore flow cells will be first stored at UPS Healthcare’s temperature-controlled distribution facility in Singapore and will be delivered within 24-48 hours via cold channel distribution from UPS to destinations across Asia-Pacific. Oxford Nanopore will also rely on UPS® Premier’s premium tracking, prioritization and traceability services for time and temperature-sensitive shipments. The goal will be same-day shipping and faster delivery of flow cells, consumables containing the technology and chemicals required for nanopore-based sequencing and working in conjunction with Oxford’s Nanopore product line.Oxford Nanopore’s investment in Asia-Pacific demonstrates its continued commitment to serving its growing customer base in the region, with numerous genomics-led research projects underway in the region. countries in the region. These include, among other things, pathogen surveillance, translational cancer research and agricultural sequencing, especially to protect shrimp farming in Malaysia.UPS Healthcare provides unparalleled healthcare logistics expertise to the scientific communities with more than 17 million square feet of GDP and GMP-compliant healthcare delivery space worldwide.This is the second Oxford Nanopore site served by UPS Healthcare, following a performance agreement signed in 2022 that currently serves the US and Canada. Plans to expand the partnership to other regions of the world, including Australia, are expected to be announced in 2023.
“We are proud to announce our expanded partnership with UPS Healthcare, which we expect to create an improved experience for our growing customer base throughout Asia Pacific. UPS’s mature infrastructure and reach globally have already improved our capacity in the US and will now allow us to increase our reach across the region without sacrificing speed or service. Through this collaboration, we are hopeful that our customers will be able to receive orders more quickly and with reduced complexity, leaving more time for the ground-breaking research critical to advancing improvements in human health, food and environments.”
Gordon Sanghera, CEO, Oxford Nanopore Technologies.
“At UPS we are focused on providing healthcare logistics capabilities and services that enable our customers to deliver lifechanging innovations with flexibility, transparency and reliability,”
“We’re excited to build on our trusted partnership with Oxford Nanopore Technologies to deliver its next-generation DNA sequencing technology to their customers in Asia Pacific, as the demand for such innovations open up possibilities for new applications and scientific research that can have a positive impact to the world.”
Ianne Loh, senior director for UPS Healthcare in Asia Pacific, Middle East and Africa.
